Company Profile

Caldera Pharmaceuticals Inc (AKA: XRPro Sciences Inc ~Icagen, Inc)
Profile last edited on: 2/17/2022      CAGE: 3VSW2      UEI:

Business Identifier: Analytical drug discovery services
Year Founded
2003
First Award
2006
Latest Award
2015
Program Status
Inactive
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

4222 Emperor Boulevard Suite 350
Durham, NC 27703
   (919) 941-5206
   info@cpsci.com
   www.cpsci.com,www.xrpro.com
Location: Single
Congr. District: 04
County: Durham

Public Profile

Spun out of technology developed at Los Alamos National Laboratory in November 2003 as Caldera Pharmaceuticals, Inc., in December 2014 name was changed to XRpro Sciences, Inc. After acquisition of assets of Icagen, Inc., the firm changed name again (to Icagen, Inc) with executive offices re-located in Durham, NC. SBIR-involved through FY 15, Caldera Pharmaceuticals had provided proprietary drug discovery services for high-throughput ion-channel inhibitor assays and enzyme activity assays. Pioneering label-free measurement of protein-drug binding, the firm's technology allows the screening of tens of thousands of protein-drug interactions per day with no modifications required for either the drug candidate or the protein. This eliminates costly and error-inducing chemical labels and provides data that more closely approximates in vivo drug behavior. The company provides real-time kinetic data on hERG channel activity on intact cell populations, and can also screen 10,000 ion-channel inhibitors in one day, as well as screen 10,000 enzyme substrates in a few hours. X-ray fluorescence is analogous to common optical fluorescence, but using an X-ray excitation light source. X-ray photons excite inner-shell electrons, causing individual atoms to fluoresce without requiring any sort of large organic fluorophores. Each chemical element emits X-ray photons with a characteristic energy. Caldera's technology has broad application - including interrogating live cells - and is compatible with standard lab automation.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 1 NIH $300,000
Project Title: Systemic Targeted Radionuclide Therapy for Cancer Treatment Period of Performance
2015 2 NIH $600,000
Project Title: Xrpro Radioactive Cesium Decorporation Agents
2013 2 NIH $3,600,000
Project Title: Xrpro Discovery Of Decorporation Agents
2012 1 AF $150,000
Project Title: Physiological testing for Hexavalent Chrome exposure in the human body
2011 2 NIH $1,095,093
Project Title: Adherence Assessment for Supplements

Key People / Management

  Gary G Altman -- President & Chief Executive Officer

  Eva R Birnbaum

  Michael Harris

  Mark Korb -- Chief Financial Officer

  Debra C Morgan -- Vice President, Corporate Development

  Lori Peterson

  Suyue Wang -- Director, Biology

  Benjamin P Warner -- Founder & Chief Scientific Officer